Amneal Pharmaceuticals
AMRX · NASDAQ
$19.84+$0.48 (+2.48%)TodayMarket closed ·
Prev close $19.36
About AMRX
- Employees
- 8,500
- Headquarters
- Bridgewater, New Jersey
- Listed
- Nov 18, 2009
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Website
- amneal.com
Leadership
| Name | Title | Since |
|---|---|---|
| Paul Meister | — | — |
| Chirag Patel | — | 2018 |
| Chintu Patel | — | 2018 |
| Anastasios Konidaris | — | — |
| Nikita Shah | — | — |
| Andrew Boyer | — | — |
| Jason Daly | — | — |
| Gautam Patel | — | — |
| Emily Alva | — | — |
| Deborah Autor | — | — |
| J. Kevin Buchi | — | 2016 |
| Jeffrey George | — | — |
| John Kiely | — | — |
| Ted Nark | — | — |
| Shlomo Yanai | — | — |
| Anthony Dimeo | — | 2022 |
Revenue by product and region
Fiscal year ended Dec 31, 2025: $3.02B total revenue
By product
- Subtotal dosage forms$1.73B57.4%
- Oral solid$726.38M24.1%
- Subtotal therapeutic classes$528.01M17.5%
- Distribution$408.46M13.5%
- Central nervous system$333.42M11.0%
- Other$1.55B51.4%
Similar companies
Companies in the same industry as Amneal Pharmaceuticals
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.